Arcus Biosciences (RCUS) – Research Analysts’ Recent Ratings Updates

A number of firms have modified their ratings and price targets on shares of Arcus Biosciences (NYSE: RCUS) recently:

• 10/21/2026 – Arcus Biosciences had its price target raised by Citigroup from $45.00 to $50.00. They now have a “buy” rating on the stock.
• 10/21/2026 – Arcus Biosciences had its price target raised by Truist Financial from $40.00 to $41.00. They now have a “buy” rating on the stock.
• 10/21/2026 – Arcus Biosciences had its price target raised by Wedbush from $43.00 to $49.00. They now have an “outperform” rating on the stock.
• 10/16/2026 – Arcus Biosciences is now covered by William Blair. They set an “outperform” rating on the stock.
• 10/15/2026 – Arcus Biosciences had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/14/2026 – Arcus Biosciences is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $41.00 price target on the stock.
• 10/3/2026 – Arcus Biosciences was upgraded by Wall Street Zen from “sell” to “hold”.
• 9/30/2026 – Arcus Biosciences had its “outperform” rating reaffirmed by Wedbush. They now have a $43.00 price target on the stock.
• 9/16/2026 – Arcus Biosciences is now covered by TD Cowen. They set a “buy” rating on the stock.
• 9/11/2026 – Arcus Biosciences had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 9/8/2026 – Arcus Biosciences had its “buy” rating reaffirmed by Truist Financial. They now have a $40.00 price target on the stock, up from $35.00.

Insiders Place Their Bets

In other Arcus Biosciences news, CAO Alexander Azoy sold 2,827 shares of Arcus Biosciences stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $30.00, for a total transaction of $84,810.00. Following the completion of the transaction, the chief accounting officer owned 39,581 shares of the company’s stock, valued at $1,187,430. The trade was a 6.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.60% of the stock is owned by corporate insiders.

Arcus Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. The company uses its research platform to discover and advance medicines designed to target immune suppression and other biological mechanisms involved in tumor growth.

Arcus’s oncology pipeline has included antibody-based and small-molecule therapies aimed at targets such as TIGIT, PD-1, CD73, and the adenosine A2A and A2B receptors. Its key development programs have included domvanalimab, zimberelimab, quemliclustat, and etrumadenant, which have been evaluated in clinical studies across several cancer types, including lung, gastrointestinal, and colorectal cancers.

Founded in 2015 and headquartered in Hayward, California, Arcus conducts research and clinical-development activities intended to support potential commercialization in international markets.